Literature DB >> 25220474

Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes.

Giuseppe Gargiulo1, Davide Capodanno, Giovanni Longo, Piera Capranzano, Corrado Tamburino.   

Abstract

NSAIDs are used worldwide by more than 30 million people everyday, given their anti-inflammatory, analgesic and antipyretic effects. NSAIDs are approved for several common adult diseases, including acute and chronic musculoskeletal or inflammatory disease, osteoarthritis, rheumatoid arthritis and other arthritic conditions, as well as for children with juvenile idiopathic arthritis. Importantly, the population commonly taking NSAIDs is that of older individuals who also represent the population with the highest risk for cardiovascular (CV) and gastrointestinal adverse effects. In recent years, a growing body of evidence regarding potential risks from chronic use of NSAIDs has emerged. The aim of this review is to update the available data concerning chronic use of NSAIDs in patients with and without CV disease by analyzing the mechanisms of action, the interference of specific NSAIDs with the established CV protective role of low-dose aspirin, and the potential increased risk of myocardial infarction, stroke, hypertension, heart failure and atrial fibrillation.

Entities:  

Keywords:  aspirin interaction; atrial fibrillation; cardiovascular disease; heart failure; hypertension; myocardial infarction; non-steroidal anti-inflammatory drugs; risk; stroke

Mesh:

Substances:

Year:  2014        PMID: 25220474     DOI: 10.1586/14779072.2014.964687

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  3 in total

1.  Green Tea Epigallocatechin-3-Gallate Suppresses Autoimmune Arthritis Through Indoleamine-2,3-Dioxygenase Expressing Dendritic Cells and the Nuclear Factor, Erythroid 2-Like 2 Antioxidant Pathway.

Authors:  Laurie S Davis; Chandra Mohan; So-Youn Min; Mei Yan; Sang Bum Kim; Sneha Ravikumar; Seong-Ryuel Kwon; Kamala Vanarsa; Ho-Youn Kim
Journal:  J Inflamm (Lond)       Date:  2015-09-15       Impact factor: 4.981

2.  Direct in situ labeling of target drugs with a fluorophore probe to improve MALDI-MS detection sensitivity in micro-liter plasma.

Authors:  Yi-Shan Li; Chi-Yu Lu
Journal:  Sci Rep       Date:  2019-07-25       Impact factor: 4.379

3.  Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.

Authors:  Joanne Ryan; Elsdon Storey; Anne M Murray; Robyn L Woods; Rory Wolfe; Christopher M Reid; Mark R Nelson; Trevor T J Chong; Jeff D Williamson; Stephanie A Ward; Jessica E Lockery; Suzanne G Orchard; Ruth Trevaks; Brenda Kirpach; Anne B Newman; Michael E Ernst; John J McNeil; Raj C Shah
Journal:  Neurology       Date:  2020-03-25       Impact factor: 11.800

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.